This chapter introduces a comprehensive overview about the principles, challenges and applications of adsorption refrigeration systems (ARSs), as a promising sustainable solution for many of cooling and heating applications. In addition to the features and the basics of ARSs, the following topics have been covered such as characteristics of working pairs, trends in improving the heat and mass transfer of the adsorber; advanced adsorption cycles and performance and operational data of some adsorption refrigeration applications. In some details, the operating range and the performance of ARSs are greatly affected by the employed working adsorbent/refrigerant pairs. Therefore, the study, development and optimum selection of adsorbent/refrigerant pairs, particularly the composite adsorbents, can lead to improving the performance and reliability of ARSs. Regarding the enhancement of heat and mass transfer in the adsorbent bed, two methods are commonly used: one is the development of adsorbents through different coating technologies or new materials such as metal-organic frameworks, and the second is the optimization of the adsorber geometrical parameters and cycle modes. Finally, a brief on some adsorption chillers applications have started to find their share in markets and driven by solar or waste heats.
5-Fluorouracil is a member of cytotoxic drugs with poor selectivity to cancer cells. Currently, systemic administration of this anti-cancer drug (oral or injection) exposes normal tissues to the drug-induced toxicity. Nowadays, attention has been greatly directed towards in situ gel-forming systems that can be injected into the affected tissues in its sol form with a minimally invasive technique. More specifically, chitosan hydrogel systems were in focus due to their antibacterial effect as well as their biodegradable, biocompatible, and mucoadhesive properties. In the present work, 5-fluorouracil was loaded on various thermosensitive chitosan hydrogel systems cross linked with different linking agents like βglycerophosphate, pluronic F127, and hydroxyapatite. Also, methotrexate was added to 5fluorouracil in order to gain its previously reported synergistic effects. Firstly, a compatibility study was performed using UV-spectrophotometric, infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) techniques to exclude the possibility of any physical or chemical interactions between the selected drugs and excipients. The prepared hydrogel systems were characterized for their physicochemical properties including organoleptic, pH, syringeability and injectability, viscosity, and gelation temperature (T gel) by various analysis techniques. Moreover, the in vitro release behavior of 5-fluorouracil and methotrexate was determined with a modified analytical method. The results indicated that chitosan hydrogel system cross-linked with a combination of βglycerophosphate, and 10 % pluronicF127 (F4) showed the most suitable physicochemical properties and release profile. Accordingly, this formula can be considered as a missionary system for localized sustained delivery of cytotoxic drugs.
Piroxicam is a potent nonsteroidal anti-inflammatory drug associated with many side effects when taken orally. An attention was paid in this work to formulate and characterize piroxicam containing polymer films for dermal use. The used polymers were Eudragit types namely Eudragit RL100, RS100, L100 and Eudragit S100. In this study, medicated films consisting of drug and carrier were prepared. The carrier consisted of one or two polymers. The physicochemical characterization was done by IR spectroscopy, DSC and X-Ray diffractometry for both piroxicam polymeric films and their corresponding physical mixtures as well as the untreated drug and polymer powders to investigate the drug polymer interaction. The results indicate presence of molecular interactions between piroxicam and both Eudragit L100 and Eudragit S100 and no interactions were found between piroxicam and Eudragit RL100 or Eudragit RS100. In-vitro drug release from Eudragit films was studied. It is found that the drug release from hydrophilic polymers is faster than that from hydrophobic ones.
All tested organogels showed a significant oedema inhibition compared with oral indomethacin ® and Voltaren® as a topical marketed anti-inflammatory drug. Moreover, the increase of drug concentration from 1% to 5% w/w is accompanied with a longer duration of action up to 12 hrs. Therefore, the formulated organogels are considered as a promising vehicle for controlled topical delivery of etodolac.
A great effort has been devoted to develop a method for delivering an efficient potent analgesic drug flurbiprofen (FLB) into more absorbed and small polymeric microparticles ethyl cellulose (EC), moreover to avoid the absorption at the acidic pH of the stomach. EC microparticles loaded with FLB were prepared by emulsion-solvent evaporation. A complete study for the encapsulation efficiency percent (EE%), the size and weight of the microparticles incorporated with FLB were studied and optimized. The release profiles of FLB from EC microparticles were measured in Sorensen phosphate buffer (0.1 M, pH 7.4). The results showed that EE% for all forms of microparticles was decreased as drug : polymer ratios decreased. The microparticles had a mean diameter of 30-80 µm as showed by scanning electron microscopy, confirming that the structure was in micro-size, moreover the release rate of FLB from microparticles was strikingly lower than that from drug itself. The results allow for the conclusion that the formulated microparticles serve as promising platform to improve the solubility, absorption and sustained release of FLB.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.